| 100.62 0.79 (0.79%) | 08-18 10:55 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 127.35  |
1-year : | 141.9 |
| Resists | First : | 109.03 |
Second : | 121.48 |
| Pivot price | 102.06 |
|||
| Supports | First : | 88.87 | Second : | 73.94 |
| MAs | MA(5) : | 99.69  |
MA(20) : | 104.96 |
| MA(100) : | 103.87 |
MA(250) : | 90.01 |
|
| MACD | MACD : | -3.9 |
Signal : | -3.6 |
| %K %D | K(14,3) : | 43.1 |
D(3) : | 40.4 |
| RSI | RSI(14): 41.1 |
|||
| 52-week | High : | 130 | Low : | 63.23 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MIRM ] has closed above bottom band by 40.0%. Bollinger Bands are 5.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 101.58 - 102.08 | 102.08 - 102.49 |
| Low: | 97.86 - 98.54 | 98.54 - 99.1 |
| Close: | 98.88 - 99.91 | 99.91 - 100.74 |
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Tue, 18 Aug 2026
Rice Hall James & Associates LLC Acquires New Position in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Tue, 18 Aug 2026
TimesSquare Capital Management LLC Invests $43 Million in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mon, 17 Aug 2026
MIRM Stock Clocks Best Day In 4.5 Months On Liver Disease Trial Data: Retail Eyes Buyout At A Premium - Stocktwits
Mon, 17 Aug 2026
Mirum Pharmaceuticals (MIRM) Q2 2026 Earnings Call Transcript - AOL.com
Sun, 16 Aug 2026
Will Mirum Pharmaceuticals' (MIRM) Widening Net Losses Test Its Growth-Focused Investment Narrative? - simplywall.st
Thu, 13 Aug 2026
Mirum Pharmaceuticals (MIRM) Stock Looks Fairly Valued After Recent News - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 61 (M) |
| Shares Float | 56 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 109.9 (%) |
| Shares Short | 7,270 (K) |
| Shares Short P.Month | 6,910 (K) |
| EPS | -14.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.05 |
| Profit Margin | -139.2 % |
| Operating Margin | -14.9 % |
| Return on Assets (ttm) | -6.8 % |
| Return on Equity (ttm) | -703 % |
| Qtrly Rev. Growth | 37.9 % |
| Gross Profit (p.s.) | 8.28 |
| Sales Per Share | 10.13 |
| EBITDA (p.s.) | -1.16 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -227 (M) |
| Levered Free Cash Flow | 77 (M) |
| PE Ratio | -7.13 |
| PEG Ratio | 0 |
| Price to Book value | 16.54 |
| Price to Sales | 9.89 |
| Price to Cash Flow | -26.91 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|